Kitov Pharma (NASDAQ:KTOV) is up premarket on the heels of providing updates on clinical progress of CM-24 and NT-219.
The company will collaborate with Bristol-Myers Squibb (NYSE:BMY)
on a Phase 1 study of CM-24 in combination with BMY’s Opdivo
(nivolumab) for non-small-cell lung carcinoma and pancreatic cancer. The
study is expected to begin in Q4 with data expected in H1 2021.
The FDA has signed off on its IND for NT-219, as
monotherapy or in combination with Erbitux, for the treatment of
recurrent or metastatic solid tumors and head and neck cancer. Phase 1
data are expected in H1 2021.
Multiple data readouts are expected within 15 months.
https://seekingalpha.com/news/3585299-kitov-pharmaplus-49-on-collaboration-bristol-myers-in-lung-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.